Auransa

The company’s AI platform uses multi-omics human disease data to identify compound candidates for responsive patients, with consistently high predictivity. It validates candidates in functional assays after testing fewer than 30 predicted compounds in the lab.

Viwat Visuthikraisee, PhD Co-founder and COO

The company’s leadership team, led by Co-Founder and CEO Pek Lum, Ph.D., has experience discovering and developing drugs at major pharmaceutical companies. The company has an industry network and understanding of complex disease biology.

Auransa is a clinical stage, AI-native biopharma with a proprietary AI platform that harnesses available human disease data to discover novel therapeutics and raise the standard of care for cancer.

Auransa begins a Phase 1 study of AU-409 by dosing its first patient. The AI-derived candidate is being studied for liver cancer and other solid tumors.

Sep 2023 · AuransaNews article

USC Norris Comprehensive Cancer Center collaborates with Auransa on a clinical trial testing a targeted treatment for liver cancer and other solid tumors. The article identifies the treatment’s focus but provides no further details about the drug or trial.

Mar 2023 · USC Norris Comprehensive Cancer CenterNews article

Auransa reports that the FDA accepted its investigational new drug (IND) application for AU-409, which is being developed to treat patients with hepatocellular carcinoma.

Nov 2022 · EIN PresswireNews article

Auransa and POLARISqb announce a research collaboration to find treatments for neglected women’s diseases. The companies use their respective discovery technologies in the effort.

Jun 2021 · PR NewswireNews article